Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

TA216 Leukaemia (lymphocytic) - bendamustine: review decision - March 2014 information

Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 103 KB)

TA216 Leukaemia (lymphocytic) - bendamustine: review proposal - December 2013 information

TA216 Leukaemia (lymphocytic) - bendamustine: Appendix A - provisional matrix of stakeholders (PDF 100 KB)

TA216 Leukaemia (lymphocytic) - bendamustine: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 296 KB)

Leukaemia (lymphocytic) - bendamustine: equality impact assessment (PDF 20 KB)

Leukaemia (lymphocytic) - bendamustine: final appraisal determination  information

Leukaemia (lymphocytic) - bendamustine: final appraisal determination document (PDF 228 KB)

Leukaemia (lymphocytic) - bendamustine: pre-meeting briefing (PDF 252 KB)

Leukaemia (lymphocytic) - bendamustine: final scope and final matrix of comsultees and commentators

Leukaemia (lymphocytic) - bendamustine: scope (PDF 46 KB)

Leukaemia (lymphocytic) - bendamustine: matrix (PDF 55 KB)

Leukaemia (lymphocytic) - bendamustine: manufacturer submission (PDF 3.18 MB)

Leukaemia (lymphocytic) - bendamustine: clarification letters

Leukaemia (lymphocytic) - bendamustine: NICE request to the manufacturer for clarification on their submission (PDF 71 KB)

Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 1 (PDF 354 KB)

Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 2 (PDF 36 KB)

Leukaemia (lymphocytic) - bendamustine: patient group, professional group and NHS organisation submissions

Leukaemia (lymphocytic) - bendamustine: British Society for Haematology and Royal College of Pathologists (joint submission) (PDF 223 KB)

Leukaemia (lymphocytic) - bendamustine: Chronic Lymphocytic Leukaemia Support Association (PDF 270 KB)

Leukaemia (lymphocytic) - bendamustine: Leukaemia CARE (PDF 34 KB)

Leukaemia (lymphocytic) - bendamustine: Lymphoma Association (PDF 173 KB)

Leukaemia (lymphocytic) - bendamustine: Royal College of Physicians / NCRI / RCR / ACP / JCCO (PDF 95 KB)

Leukaemia (lymphocytic) - bendamustine: United Kingdom Chronic Lymphocytic Leukaemia Forum (PDF 212 KB)

Leukaemia (lymphocytic) - bendamustine: Expert personal perspectives

Leukaemia (lymphocytic) - bendamustine: Jane Barnard nominated (PDF 15 KB)

Leukaemia (lymphocytic) - bendamustine: Dr Chris Fegan (PDF 16 KB)

Leukaemia (lymphocytic) - bendamustine: Professor Andrew Pettitt (PDF 14 KB)

Leukaemia (lymphocytic) - bendamustine: Chonette Taylor (PDF 13 KB)

Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report (PDF 1.63 MB)

Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report - factual accuracy check (PDF 53 KB)

Leukaemia (lymphocytic) - bendamustine: response to consultee and commentator comments on the draft scope (PDF 87 KB)

Leukaemia (lymphocytic) - bendamustine: institutes response to consultee and commentator comments on the provisional matrix (PDF 22 KB)

Leukaemia (lymphocytic) - bendamustine: final matrix (PDF 31 KB)

Leukaemia (lymphocytic) - bendamustine: final scope (PDF 26 KB)

Appendix C - provisional matrix (pre-referral) - November 2009 (PDF 55 KB)

Appendix B - draft scope for consultation (pre-referral) - November 2009 (PDF 47 KB)